The Effect of Intramuscular 17α-Hydroxyprogesterone in Women Screened for Shortened Cervical LengthFunding None.
17 May 2019
14 October 2019
22 November 2019 (online)
Objective This article assesses the effect of weekly intramuscular 17α-hydroxyprogesterone caproate (17P) on midtrimester cervical length (CL) in patients with prior spontaneous preterm birth.
Study Design Retrospective cohort study of all singletons that underwent CL screening at a single institution from 2011 to 2016. The timing of 17P exposure was assessed. The primary outcome was shortest midtrimester CL. Secondary outcomes included gestational age at delivery, rate of short cervix, cerclage, preterm labor admission, and preterm premature rupture of the membranes (PROM). Multivariable regression analysis was used to model the relationship between 17P exposure and shortest CL, controlling for selected covariates.
Results Of 409 women who underwent screening, 211 received and 198 did not receive 17P prior to the last CL. Rates of short cervix and cerclage were similar between groups. After adjusting for covariates, the shortest CL was significantly shorter in the 17P group. In a secondary analysis, those who received any 17P (n = 293) versus those who did not (n = 116) had higher rates of preterm PROM, preterm labor admission, and cerclage. After controlling for covariates, gestational age at delivery was significantly lower in those receiving 17P.
Conclusion In high-risk patients undergoing CL screening for ultrasound-indicated cerclage, 17P did not prevent midtrimester cervical shortening or prolong gestation.
Keywordscervical length screening - preterm birth - effect of progesterone - recurrent preterm birth prevention - cerclage
This study was presented in part at the 2017 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting, San Diego, CA, May 6–9, 2017.
- 1 American College of Obstetricians and Gynecologists. Prediction and prevention of preterm birth. Practice Bulletin No. 130. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012; 120: 964-973
- 2 Meis PJ. ; Society for Maternal-Fetal Medicine. 17 hydroxyprogesterone for the prevention of preterm delivery. Obstet Gynecol 2005; 105 (5 Pt 1): 1128-1135
- 3 Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol 2012; 206 (05) 376-386
- 4 Society for Maternal-Fetal Medicine (SMFM) Publications Committee. The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth. Am J Obstet Gynecol 2017; 216 (03) B11-B13
- 5 American College of Obstetricians and Gynecologists. Cerclage for the management of cervical insufficiency. Practice Bulletin No. 142. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014; 123 (2 Pt 1): 372-379
- 6 Owen J, Hankins G, Iams JD. , et al. Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length. Am J Obstet Gynecol 2009; 201 (04) 375.e1-375.e8
- 7 Berghella V, Rafael TJ, Szychowski JM, Rust OA, Owen J. Cerclage for short cervix on ultrasonography in women with singleton gestations and previous preterm birth: a meta-analysis. Obstet Gynecol 2011; 117 (03) 663-671
- 8 Berghella V, Ludmir J, Simonazzi G, Owen J. Transvaginal cervical cerclage: evidence for perioperative management strategies. Am J Obstet Gynecol 2013; 209 (03) 181-192
- 9 Iams JD, Johnson FF, Sonek J, Sachs L, Gebauer C, Samuels P. Cervical competence as a continuum: a study of ultrasonographic cervical length and obstetric performance. Am J Obstet Gynecol 1995; 172 (4 Pt 1): 1097-1103
- 10 Sonek JD, Iams JD, Blumenfeld M, Johnson F, Landon M, Gabbe S. Measurement of cervical length in pregnancy: comparison between vaginal ultrasonography and digital examination. Obstet Gynecol 1990; 76 (02) 172-175
- 11 Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health. Available at: www.openepi.com . Accessed April 22, 2017
- 12 Durnwald CP, Lynch CD, Walker H, Iams JD. The effect of treatment with 17 alpha-hydroxyprogesterone caproate on changes in cervical length over time. Am J Obstet Gynecol 2009; 201 (04) 410.e1-410.e5
- 13 Berghella V, Figueroa D, Szychowski JM. , et al; Vaginal Ultrasound Trial Consortium. 17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Am J Obstet Gynecol 2010; 202 (04) 351.e1-351.e6
- 14 Szychowski JM, Berghella V, Owen J. , et al; Vaginal Ultrasound Trial Consortium. Cerclage for the prevention of preterm birth in high risk women receiving intramuscular 17-α-hydroxyprogesterone caproate. J Matern Fetal Neonatal Med 2012; 25 (12) 2686-2689
- 15 Rafael TJ, Mackeen AD, Berghella V. The effect of 17α-hydroxyprogesterone caproate on preterm birth in women with an ultrasound-indicated cerclage. Am J Perinatol 2011; 28 (05) 389-394
- 16 Mackeen AD, Rafael TJ, Zavodnick J, Berghella V. Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage. Am J Perinatol 2013; 30 (09) 755-758
- 17 Rebarber A, Cleary-Goldman J, Istwan NB. , et al. The use of 17 alpha-hydroxyprogesterone caproate (17P) in women with cervical cerclage. Am J Perinatol 2008; 25 (05) 271-275
- 18 Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A. Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007; 196 (05) 453.e1-453.e4
- 19 Heyborne KD, Allshouse AA, Carey JC. Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?. Am J Obstet Gynecol 2015; 213 (06) 844.e1-844.e6
- 20 Iams JD. Identification of candidates for progesterone: why, who, how, and when?. Obstet Gynecol 2014; 123 (06) 1317-1326
- 21 Blackwell SC, Gyamfi-Bannerman C, Biggio Jr JR. , et al. PROLONG clinical study protocol: Hydroxyprogesterone caproate to reduce recurrent preterm birth. Am J Perinatol 2018; 35 (12) 1228-1234
- 22 Nelson DB, McIntire DD, McDonald J, Gard J, Turrichi P, Leveno KJ. 17-alpha hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study. Am J Obstet Gynecol 2017; 216 (06) 600.e1-600.e9